Investigator-initiated studies

Investigator-Initiated Studies

Novavax is committed to supporting research that serves the healthcare community and the public. To fulfill this commitment, Novavax supports independent research through our Investigator-Initiated Studies (IIS) program. An IIS is defined as a research study that is sponsored, initiated, and conducted by an investigator unaffiliated with Novavax.

The Novavax IIS program supports clinical and non-clinical research that addresses important unmet scientific or medical needs aligned with Novavax’s areas of interest. Support for an approved IIS may include funding, Novavax product, or both.

IIS proposals are reviewed on a rolling basis. For questions about the IIS program or the application process, please contact Novavax at [email protected]

Areas of research interest

Novavax will consider unsolicited, hypothesis-driven IIS proposals related to COVID-19 and the Novavax COVID-19 investigational vaccine in the following areas:

  • Durability of COVID-19 vaccine protection
  • COVID-19 vaccine correlates of protection
  • Cross-strain variant protection
  • Co-administration with other approved vaccines
  • Use of vaccine as a booster (e.g., heterologous boosting) including safety profile and efficacy after multiple doses
  • Specific populations, including pregnant women, immunocompromised individuals, pediatrics, and other at-risk or vulnerable populations
  • Evaluation of COVID-19 vaccine effectiveness on duration of illness during initial infections, breakthrough infections, severe outcomes, long COVID or other effectiveness studies
  • Evaluation of safety and/or effectiveness of COVID-19 vaccination in low- and middle-income countries (LMICs)

The Novavax IIS program is not able to support requests for participation in collaborative research studies, Novavax-sponsored clinical studies, and/or preclinical studies, requests for clinical study samples or expanded access programs.